Overview of Keta-S

What is Keta-S? Identity, Classification, and Core Action

Property	Description
Active ingredient	Esketamine
Form	Aqueous solution (for injection), Nasal spray
Pharmacological class	NMDA Receptor Antagonist, General Anesthetic, Antidepressant
Typical use (General)	Anesthesia and Rapid-Acting Mood Modulation
Origin	Synthetic compound, Pure S-enantiomer (dextrorotatory)
Prescription Status	Prescription-Only (Rx)

The Core Identity: What Type of Medicine is Esketamine?

Keta-S is a pharmaceutical preparation whose active ingredient is Esketamine, classified primarily as an NMDA Receptor Antagonist based on its fundamental mechanism of action. Esketamine is a synthetic single compound product and is recognized for its dual roles as both a potent General Anesthetic and a unique type of Antidepressant. The drug is consistently used in controlled settings where a rapid and profound pharmacological effect is necessary, a characteristic clinically recognized for managing high-risk anesthetic scenarios.

Composition and Origin: How Does Esketamine Differ from Ketamine?

The substance Esketamine is chemically defined as the S-(+)-enantiomer of the parent drug, ketamine. This distinction is a key differentiating feature because racemic ketamine, the widely used anesthetic, consists of an equal mixture of the S-enantiomer and the R-enantiomer (Arketamine). Esketamine, as the isolated S-form, exhibits a three to fourfold greater binding affinity for the primary molecular target than the R-enantiomer. The selective use of the more potent S-enantiomer is intended to target the desired therapeutic effects with higher efficiency. Esketamine is typically formulated as an aqueous solution for intravenous administration in anesthesia and as a specialized nasal spray for intranasal use in psychiatric contexts, offering distinct routes for optimized clinical delivery.

General Therapeutic Purpose

The overall function of Esketamine is linked directly to its capacity to non-competitively block the NMDA receptor, thereby rapidly modulating glutamate neurotransmission in the central nervous system. This specific mechanism enables the medicine to achieve two general therapeutic benefits: it can be used to induce deep, controlled anesthesia and profound analgesia, or, at lower, controlled levels, it can provide a rapid-acting intervention to stabilize neural circuits involved in severe mood disorders. This approach provides a novel, fast-acting treatment option for complex mental health conditions.

Regulatory References

Antidepressants - StatPearls - NCBI Bookshelf

What side effects are possible with Keta-S?

Possible side effects and safety information

The official safety documentation for Keta-S details its adverse reaction profile based on frequency and the body system affected. Very Common reactions, reported in 10% or more of patients, include Dissociation, Dizziness, Nausea, Somnolence (Sedation), Vertigo, Headache, and Dysgeusia (taste alteration). Effects classified as Common include Anxiety, Increased Blood Pressure, Increased Heart Rate, and Blurred Vision.

Adverse events are formally grouped into System-Organ Classes, with the most frequently affected being the Nervous System Disorders and Psychiatric Disorders.

The official labeling includes a Boxed Warning highlighting serious safety concerns such as Sedation, Dissociation, Respiratory Depression, Abuse and Misuse Potential, and the risk of Suicidal Thoughts and Behaviors. The risk of Hemorrhagic Cystitis (bladder inflammation) is also documented, associated with prolonged, high-dose exposure.

Safety-related restrictions require the medicine is contraindicated in patients with a history of Aneurysmal Vascular Disease or conditions where an increase in blood pressure or intracranial pressure poses a serious risk. Use in patients with Severe Hepatic Impairment (Child-Pugh Class C) is not recommended. The dissociative and cardiovascular effects (e.g., blood pressure increase) are typically transient, occurring shortly after administration and resolving within a few hours.

These safety classifications, as defined by regulatory agencies like the FDA and EMA, structure the understanding of the medicine’s risk profile by clearly communicating both common, expected effects and the critical, label-derived safety restrictions.

Overdose and Emergency Response

Keta-S Overdose and When to Seek Help

Overdose information for Keta-S (Esketamine) is based on reports of high-dose exposure and the drug's established pharmacological profile, as documented in regulatory sources such as the FDA and EMA.

Documented Overdose Presentations

Domain	Official Regulatory Statement
Documented Overdose Manifestations	Symptoms include profound sedation, dissociation or perceptual changes, and loss of consciousness. Other noted effects include dizziness, vomiting, and a feeling of being drunk [Source: FDA, EMA].
Physiological Systems Affected	The primary systems affected are the CNS and Cardiorespiratory System, manifesting as respiratory depression, respiratory arrest (rare reports), and a substantial increase in blood pressure (Hypertension) [Source: FDA, EMA].
Population-specific Notes	The drug is contraindicated in patients for whom an increase in blood pressure or intracranial pressure poses a serious risk. Patients with underlying cardiovascular and cerebrovascular conditions may be at an increased risk of adverse effects during high-dose exposure [Source: FDA, EMA].

Emergency Response and Management

Classification	Official Regulatory Statement
Antidote Information	No specific antidote is known for Esketamine overdose. Management is primarily based on symptomatic and supportive treatment.
Monitoring Requirement	Patients must be monitored for at least 2 hours after administration, followed by an assessment for clinical stability prior to leaving the healthcare setting.
When Immediate Medical Help is Required	Seek immediate medical attention for severe symptoms such as trouble breathing, signs of respiratory distress, collapse, or loss of consciousness [Source: NIH/MedlinePlus]. The possibility of multiple drug involvement should be considered.

The official overdose profile highlights the potential for severe CNS and cardiorespiratory events, including respiratory arrest and loss of consciousness. Regulators mandate that emergency help must be sought immediately when life-threatening symptoms, such as significant changes in breathing or collapse, are observed.

Therapeutic Uses of Keta-S

What Keta-S treats: main uses and benefits

The medication is applied across domains where additional symptomatic support is needed. The therapeutic domains include conditions characterized by periods of heightened symptoms like treatment-resistant major depressive disorder, acute suicidal ideation and related manifestations, and general anesthesia in medical settings. For patients facing treatment failure, this medication supports the patient during difficult episodes by easing the overall burden of chronic illness.

Keta-S is commonly used in clinical settings marked by heightened patient distress, is applied in addressing groups of symptoms that appear suddenly. The therapeutic benefit is assistance with maintaining functional stability and symptom stabilization.

Quick Fact: Relevant for Acute Symptom Management

Additionally, this medicine is considered relevant in clinical settings requiring temporary assistance in symptom stabilization, serving as an agent for general anesthesia and is applied in scenarios where additional management of discomfort is required. It may assist with maintaining functional stability and supporting a managed experience of analgesia. “It contributes to easing the overall symptom load for patients facing chronic or acute difficulties.”

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Keta-S — official regulatory information

Eligibility Category	Official Regulatory Statement
Populations for whom use is allowed (as stated in label)	Approved for use in Adults (18 years of age and older).
Populations for whom use is not recommended (if applicable)	Not recommended for patients with severe hepatic impairment (Child-Pugh Class C).
Populations for whom use is contraindicated	Patients with aneurysmal vascular disease (including intracranial, thoracic, or abdominal aorta, or peripheral arterial vessels) must not use the medicine.
	Patients with a history of intracerebral hemorrhage must not use the medicine.
	Contraindicated in patients with known hypersensitivity to esketamine, ketamine, or any formulation excipients.
Age-related eligibility rules	Not approved for use in pediatric patients (aged 17 years and younger); safety and efficacy have not been established.
Condition-specific eligibility rules	Use in patients with moderate hepatic impairment (Child-Pugh Class B) requires caution and extended monitoring.
	Patients with unstable or poorly controlled hypertension should be carefully assessed before prescribing.
Pregnancy and lactation eligibility status (if explicitly documented)	Use during pregnancy may cause potential fetal harm. Females of reproductive potential must use an effective method of contraception.
	Breastfeeding is not recommended due to the potential presence of the active ingredient in human breast milk and risk to the infant.

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents): Contraindicated, Not Recommended, Caution, Not Established.
Regulatory basis (EMA / FDA / etc.): EMA Product Information (SmPC), FDA Prescribing Information, Health Canada Product Monograph.

Resulting eligibility structure

Patients with aneurysmal vascular disease or a history of intracerebral hemorrhage are formally contraindicated from using the medicine.
The medicine is restricted to adults (aged 18 and older) because safety and efficacy have not been established in the pediatric population.
Use is not recommended in patients with severe hepatic impairment and requires specific caution in those with moderate hepatic impairment or unstable hypertension.
Use during pregnancy is explicitly associated with a risk of fetal harm, requiring women of childbearing potential to use effective contraception throughout the treatment period.

Connection to the overall eligibility profile

Regulatory documents define the eligibility profile of Keta-S by establishing clear population boundaries through absolute contraindications based on specific vascular and cerebral conditions. Eligibility is further structured by age restrictions, formally limiting use to adults, and by comorbidity-dependent limitations which advise against use or require special caution for patients with specific levels of hepatic impairment or uncontrolled hypertension. This formal structure precisely dictates who can and cannot initiate treatment according to governmental labeling standards.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Co-administration of Keta-S with other substances is documented across three primary domains: additive pharmacodynamic effects, pharmacokinetic clearance modification, and administration timing rules.

Additive Pharmacodynamic Effects

CNS Depressants: Combining Keta-S with Central Nervous System (CNS) Depressants, such as opioids or benzodiazepines, carries an increased risk of severe sedation and respiratory depression. Close monitoring is required during co-administration.
Cardiovascular Stimulants: Concomitant use with Psychostimulants or Monoamine Oxidase Inhibitors (MAOIs) may lead to an increase in blood pressure. Monitoring of cardiovascular status is necessary.

Pharmacokinetic and Exposure Alterations

CYP Enzymes: Keta-S is primarily metabolized by CYP3A4 and CYP2B6 enzymes. Although CYP inhibitors and CYP inducers are documented to alter Esketamine's systemic exposure (AUC changes up to 33%), official regulatory guidance states that a dose adjustment is not warranted for these interactions.
Hepatic Impairment: Patients with moderate hepatic impairment (Child-Pugh Class B) exhibit higher systemic exposure and a prolonged half-life, necessitating extended monitoring.

Timing and Product Restrictions

Oral/Nasal Products: Mandatory administration timing rules require avoiding food for at least 2 hours and liquids for at least 30 minutes prior to dosing. Nasal corticosteroids or nasal decongestants must be administered at least 1 hour before Keta-S nasal spray.
IV Chemical Incompatibility: The intravenous formulation of Esketamine is chemically incompatible with barbiturates, diazepam, and doxapram due to precipitate formation.

Mechanism of Action

How Keta-S Works

Keta-S primarily works by modulating signaling within the central nervous system (CNS), affecting key neurotransmitter pathways to produce its physiological effects. The drug engages multiple receptors and ion channels, leading to a profound shift in neuronal activity and communication.

Modulation of Glutamatergic Signaling

This action centers on the drug's role as a non-competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor. By binding within the ion channel, Keta-S blocks the excitatory neurotransmission mediated by glutamate. This modification of early molecular steps within the signaling cascade results in the suppression of high-frequency neuronal activity, which alters subsequent systemic physiological outcomes.

Influencing Monoamine Neurotransmitter Systems

Keta-S engages mechanisms by affecting the reuptake or activity of monoamine neurotransmitters such as dopamine, norepinephrine, and serotonin. This influence on distinct signaling patterns modulates the processes driven by these mediators, leading to changes in systemic physiological parameters that characterize the drug's mechanism of action.

Dosage and Administration Information

How to Use Keta-S

Keta-S (Esketamine) is administered via the intranasal route using a single-use nasal spray device. The medicine is subject to highly specific administration rules.

Official Administration Protocol

Keta-S must be administered under the direct supervision of a healthcare provider in a certified treatment center. Following administration, patients are required to remain monitored in the healthcare setting for a mandatory period of at least 2 hours.

Dosing Schedule and Frequency

The standard adult regimen for treatment-resistant depression is structured into two main phases. The usual starting dose on Day 1 is 56 mg. For the initial Induction Phase (Weeks 1 to 4), the medicine is administered twice per week. The schedule then transitions to the Maintenance Phase (beginning Week 5), where the frequency is reduced to either once weekly or every 2 weeks, individualized to the least frequent dose that sustains response.

Indication Dosing Rules	Guideline
TRD Initial Dose	56 mg on Day 1; subsequent doses 56 mg or 84 mg
MDD with Suicidal Ideation	Standard dose of 84 mg

Contextual Use Instructions

Specific rules govern patient preparation. To ensure proper use, patients should avoid food for at least 2 hours and liquids for at least 30 minutes prior to administration. If multiple nasal spray devices are required for the prescribed dose (e.g., 84 mg), a waiting period of 5 minutes is mandated between the use of each device.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Keta-S

Evidence for Use in Treatment-Resistant Major Depressive Disorder (TRD)

Research exploring how symptoms change over time for TRD has mainly relied on short-term, controlled studies where the compound was evaluated alongside a newly started oral antidepressant. These studies compare how patients who received the compound fared against those who received a placebo (an inactive substance) along with the oral antidepressant. Researchers examined outcomes related to systemic or functional imbalance, specifically by measuring changes in standardized depressive symptom severity scores and monitoring how many patients reached remission or response during the short, initial treatment phase. Findings describe patterns observed in these short-term studies, and the research reports measurements taken during the study period. Long-term effects are not fully established; certainty remains low regarding how long the effects may last after the compound is stopped, and there is limited information for long-term outcomes of patients returning to their baseline status.

Evidence for Use in Major Depressive Disorder with Acute Suicidal Ideation

The compound was studied for use in patients experiencing conditions involving periods of heightened symptoms, specifically major depression accompanied by acute suicidal thoughts or behavior. These were research exploring short-term symptom changes, where patients were already receiving comprehensive, supervised care. Researchers monitored outcomes related to episodic or acute changes in both overall depressive symptoms and scores from suicidality-specific rating scales at very close time intervals. Data show patterns related to limited certainty regarding the reduction of suicidal behavior itself. The studies were designed to assess changes in symptoms, and the research did not provide data on whether an individual will experience a reduction in actual suicidal acts.

Research Overview for General Anesthesia and Pain Relief

The compound was studied for its use as a general anesthetic and for analgesic purposes. Research examined the use of the compound (via the intravenous route) in inducing and maintaining a controlled anesthetic state. The outcomes monitored physiological strain or stress, including measures of hemodynamic stability. Specifically, the nasal spray formulation has not been studied for or established as an agent for general anesthesia, meaning its use in that context remains uncertain.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Keta-S (FAQ)

Q: How quickly does Keta-S typically start to work after administration?

According to official product information, the medicine’s concentration in the blood typically reaches its peak between 20 to 40 minutes after administration. Clinical trials for its use in severe depression also measured effectiveness as early as 24 hours after the first dose.

Q: What is the expected duration of the effects of Keta-S?

The most immediate psychological effects, such as feelings of detachment, are transient, generally beginning shortly after the medicine is given and resolving within the mandatory 2-hour monitoring period. The medicine’s presence in the body is described by an elimination half-life of approximately 7 to 12 hours.

Q: Can Keta-S cause memory problems or confusion?

Yes, official safety documents indicate that Keta-S may temporarily impair attention, judgment, and thinking skills. Confusion about time, place, and identity is a documented potential side effect, along with difficulty thinking or remembering.

Q: Are the common side effects of Keta-S temporary?

The official safety information confirms that the dissociative effects (feeling detached) and increases in blood pressure are typically transient. These effects are expected to begin resolving within a few hours following administration, which is why patients are monitored during this initial period.

Q: Is it safe to drive or operate machinery after Keta-S administration?

Official prescribing information advises that patients must not drive or operate machinery until the next day following a restful night’s sleep after using Keta-S. The restriction is in place because the medicine may temporarily impair cognitive function and motor skills.

Q: Is Keta-S linked to bladder or urinary issues?

Yes, official labeling includes a warning regarding the risk of Hemorrhagic Cystitis, which is bladder inflammation. This is a documented safety concern and is generally associated with prolonged, high-dose exposure. Frequent, urgent, painful, or burning urination is also listed as a potential side effect.

Q: What is the risk of overdose with Keta-S?

Overdose is a documented risk noted in official safety information. Regulatory bodies state that the possibility of multiple drug involvement should be considered in overdose scenarios, and information for managing an overdose is available from certified poison control centers.

Q: Can Keta-S affect the function of the kidneys or liver?

Regulatory documents address use in patients with liver impairment, noting that use is not recommended for severe hepatic impairment. Clinical data indicates that a dosage adjustment is not typically required in patients with renal (kidney) impairment.

Q: What should a patient do if the effects of Keta-S seem too strong or 'scary'?

Since Keta-S is administered only under the direct supervision of a healthcare provider in a certified center, the established protocol requires patients to remain monitored for at least 2 hours. This period of observation, required by regulatory guidelines, allows the healthcare team to monitor for and address immediate adverse reactions, such as severe sedation or dissociation.

Q: Does Keta-S cause psychological dependence or addiction?

Official labeling includes a Boxed Warning regarding the medicine’s Abuse and Misuse Potential, and it is classified as a Schedule III controlled substance. As a result of this potential, patients are closely monitored for signs and symptoms of abuse and misuse during treatment.

Q: What happens if I miss a scheduled administration of Keta-S?

Official guidance states that a healthcare provider will determine the appropriate plan if a treatment session is missed. If depressive symptoms have worsened, the provider may consider reverting the patient to a previous, more frequent dosing schedule until symptoms stabilize.

Q: Are there different forms of Keta-S available (e.g., nasal spray vs. injection)?

The active ingredient, Esketamine, is available as a nasal spray for its approved psychiatric indications. While the parent compound is also available as an intravenous solution for other uses, the nasal spray formulation is not approved to be used as an anesthetic agent.

Q: Can Keta-S be used for conditions other than its main regulatory approval (descriptive)?

The nasal spray formulation has specific approvals for treatment-resistant depression and for major depressive disorder with acute suicidal ideation or behavior. Official regulatory documents explicitly state that the nasal spray is not approved for use as an anesthetic agent.

Q: Are the research findings on Keta-S considered definitive?

Regulatory documents describe the findings in terms of short-term study results and advise that certainty remains low regarding how long the therapeutic effects may last after the medicine is stopped. Official guidelines emphasize the importance of continued, periodic assessment of the medicine’s benefit.

Q: Does Keta-S stay in the system for a long time?

The compound has an elimination half-life of approximately 7 to 12 hours. However, the immediate psychological and cardiovascular effects typically resolve much faster, within the first two hours after administration.

Q: What is the expected length of a typical course of Keta-S treatment?

Official dosing guidelines establish an initial Induction Phase of twice-weekly dosing for 4 weeks, followed by an individualized Maintenance Phase. The total duration of treatment is not fixed and is subject to the healthcare provider's periodic assessment of the medicine’s ongoing therapeutic benefit.

Q: Do studies support the use of Keta-S for chronic pain management?

Official research summaries state that the compound was studied for its analgesic purposes (pain relief). However, the nasal spray formulation is not currently approved or established for use in general anesthesia or for the management of chronic pain.

Q: Are there certain ethnic or genetic populations that respond differently to Keta-S?

Official reports and literature reviews have noted that some populations, including non-White and Hispanic/Latinx individuals, have been underrepresented in key clinical trials. Official literature notes that data on potential differences in response across diverse genetic and ethnic groups may be limited.

Q: How does Keta-S affect sleep patterns?

The official safety information lists difficulty falling asleep or staying asleep, known as insomnia, as a potential side effect of the medicine.

Q: Can Keta-S cause a temporary increase in anxiety or vivid dreams?

Official safety information lists Anxiety as a Common side effect. Unusually vivid dreams or nightmares are also documented as potential less common side effects of the medicine.

Q: Does the official safety information for Keta-S discuss risk of self-harm?

The FDA Prescribing Information includes a Boxed Warning regarding the increased risk of Suicidal Thoughts and Behaviors, especially in young adults. This is the primary context for related risks discussed in the official documents.

Q: Why is Keta-S used in emergency or surgical settings?

The compound is valued in certain critical and surgical settings because its mechanism of action provides rapid analgesic (pain-relieving) and sedative effects. It is also noted to have a potential advantage over other agents in maintaining hemodynamic stability (stable blood pressure and heart rate).

Q: Are there any long-term side effects associated with regulated Keta-S use?

Long-term data is limited, especially regarding sustained efficacy. However, the risk of serious long-term conditions like Hemorrhagic Cystitis (bladder inflammation) is documented, primarily in official warnings associated with prolonged, high-dose exposure.

How should Keta-S be stored and disposed of?

Storage and Disposal of Esketamine Nasal Spray

Storage of esketamine nasal spray must adhere to specific controlled substance and temperature requirements established by regulatory documents.

Storage Conditions

Requirement	Official Specification
Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection	Must be kept protected from light and kept from freezing.
Security	As a Schedule III controlled substance, the product must be kept in a secure place and out of the reach of children.

Handling and Disposal

The single-use device must be used or disposed of within 14 days of its receipt in the certified healthcare setting if unused. All used, unused, or partially used devices must be disposed of as medical waste following federal, state, and local regulations for controlled substances. Healthcare professionals are required to wear protective gloves when handling the used device during disposal.

Keta-S